ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Vir Biotechnology and Alnylam Pharmaceuticals Initiate Phase 1/2 Study of VIR-2218
November 28, 2018Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc. announced the initiation of a Phase 1/2 study of VIR-2218, a novel, investigational RNA interference (RNAi) therapeutic for the treatment ....... -
China's NMPA approves Gilead's Vemlidy for HBV
November 20, 2018HBV is highly prevalent in China with an estimated 20 million people meeting current guidelines for therapy accounting -
China's NMPA approves Gilead's Vemlidy for HBV
November 20, 2018HBV is highly prevalent in China with an estimated 20 million people meeting current guidelines for therapy – accounting for almost one-third of all patients currently requiring therapy worldwide. -
Hepatitis B Drug Market to Reach RMB 20 Billion in China by 2020
November 01, 2018A Brief Description of Anti-Hepatitis B Drugs -
Eisai's Lenvima gets nod in China for liver cancer treatment
September 07, 2018HBV is considered to be a negative predictor of tumor response to existing drug therapies. -
Sensitive new assay detects hepatitis B infection in single liver cells and serum
April 16, 2018Technique measuring the cccDNA marker may allow earlier detection of hepatocellular carcinoma in patients…
Pharma Sources Insight January 2025
